GlassScriptPhysician profile
Zeyad Alsaeedi
NPI 1083423867
$471.59
in general payments reported to CMS, 2019-2025
14 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $86.64 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $84.76 | 2025 | Glassia |
| Viatris Specialty LLC | $46.50 | 2025 | Yupelri |
| Baxter Healthcare | $41.44 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Ani Pharmaceuticals, INC. | $30.40 | 2025 | Purified Cortrophin Gel |
| Philips North America LLC | $29.84 | 2025 | Encore, Vest Therapy Und |
| Avadel Cns Pharmaceuticals, LLC | $24.37 | 2025 | Lumryz |
| Amgen INC. | $20.89 | 2025 | Tavneos |
| Regeneron Healthcare Solutions, INC. | $20.17 | 2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $19.04 | 2025 | Opsumit |
| United Therapeutics Corporation | $18.26 | 2025 | Tyvaso |
| Merck Sharp & Dohme LLC | $18.21 | 2025 | Winrevair |
| Astrazeneca Pharmaceuticals LP | $17.40 | 2025 | Tezspire |
| 3b Medical, INC. | $13.67 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeyad Alsaeedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.